A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety & Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects with Moderately to Severely Active Ulcerative Colitis